Cover Image
市場調查報告書

老齡化黃斑變色症 (AMD)的全球市場:未來展望

Global Age-related macular degeneration Market - Global Forecast Till 2023

出版商 Market Research Future 商品編碼 667511
出版日期 內容資訊 英文 217 Pages
訂單完成後即時交付
價格
Back to Top
老齡化黃斑變色症 (AMD)的全球市場:未來展望 Global Age-related macular degeneration Market - Global Forecast Till 2023
出版日期: 2018年06月29日 內容資訊: 英文 217 Pages
簡介

本報告提供全球老齡化黃斑變色症 (AMD)的相關市場相關分析,疾病概要和市場基本結構、最新形勢,整體市場趨勢預測 (過去2年、今後6年份),疾病的各特徵、各產品區隔、各地區的詳細趨勢,市場競爭環境,主要企業簡介等調查。

第1章 序論

第2章 摘要整理

第3章 市場概要

第4章 分析方法

第5章 市場動態

  • 簡介
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 開發中產品分析 (共11項產品)

第6章 市場要素分析

  • 供應鏈分析
    • 研究開發
    • 零件製造
    • 流通
    • 行銷、銷售
    • 售後服務、監測
  • 波特的五力分析

第7章 全球老齡化黃斑變色症 (AMD) 市場:各類型

  • 概要
    • 簡介
    • 滲出型 (溼型) AMD
    • 萎縮型 (乾型) AMD

第8章 全球AMD市場:各階段

  • 概要
    • 簡介
    • 早期階段AMD
    • 後期階段AMD

第9章 全球AMD市場:各年齡層

  • 概要
    • 簡介
    • 75歲以上
    • 60歲以上
    • 40歲以上

第10章 全球AMD市場:各診斷/治療

  • 概要
    • 簡介
    • 治療
    • 診斷

第11章 全球AMD市場:各投藥途徑

  • 概要
    • 簡介
    • 玻璃體內給藥
    • 靜脈內用途

第12章 全球AMD市場:各終端用戶

  • 概要
    • 簡介
    • 醫院、診所
    • 診斷中心
    • 教育、研究機關

第13章 全球AMD市場:各地區

  • 概要
  • 南北美洲
    • 北美 (美國,加拿大)
    • 南美
  • 歐洲
    • 西歐 (德國,法國,英國,義大利,西班牙等)
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 中東、非洲
    • 中東
    • 非洲

第14章 競爭環境

  • 各企業市場佔有率分析
  • 主要策略分析

第15章 企業的簡介

  • Novartis AG
    • 企業概要
    • 主要的財務指標
    • 主要產品
    • 近幾年主要的動向
    • SWOT分析
    • 主要策略
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Acucela Inc.
  • Ophthotech Corporation
  • GlaxoSmithKline Plc.
  • Bayer AG
  • Rxi Pharmaceuticals, Inc.
  • Regeneron Pharmaceutical Inc.
  • Alimera Sciences Inc.
  • Santen Pharmaceuticals co.
  • ALLERGAN
  • Bausch & Lomb Incorporated

第16章 附錄

目錄

Introduction

Age-Related Macular Degeneration (AMD) is a condition that affects the back of the eye called the macula. AMD is described as either dry or wet AMD.

Age-related macular degeneration causes progressive damage to the macula, resulting in gradual loss of central vision. There are two types of AMD, namely, dry (nonexudative or atrophic), and wet (neovascular or exudative). About 80 to 90% of the people with AMD have only the dry type. The market growth is mainly driven by the rising prevalence of AMD in the geriatric population and off-patent of blockbuster drugs.

Age-related macular degeneration is an ocular disease that involves the posterior aspect of the retina called the macula. The wet form of AMD is less frequent but is responsible for 90% of the acute blindness due to AMD.

As per the study published in the Asia-Pacific Journal of Ophthalmology in 2017, the global prevalence of AMD was nearly 8.7%, with the prevalence of early AMD and late AMD being 8.0% and 0.4%, respectively. A marked increase in the prevalence of AMD was found to be higher in patients over 60 years of age. According to the study published in the Clinical Interventions in the Aging Journal in 2017, AMD is a major cause of central visual loss which affects nearly 10% of the people older than 65 years and more than 25% of people older than 75 years. It is also reported that in the US approximately 2 million individuals have advanced AMD and more than 8 million individuals have an intermediate form of the disease. The number is expected to rise by 50% by 2020.

On the other hand, certain factors restraining the growth of the market include the high cost associated with AMD. The current mainstay of treatment for AMD is anti-Vascular Endothelial Growth Factor agents (anti-VEGF) with demonstrated efficacy in improving visual acuity. There are various anti-VEGF drugs available to treat AMD, but three are most commonly used for the condition. Two of these, namely, Lucentis (ranibizumab) and Eylea (aflibercept) are specifically designed and are FDA-approved for the treatment of AMD. The third drug, Avastin (bevacizumab) was originally developed to treat cancer but is commonly used off-label in patients with AMD.

The average cost of AMD treatment with Lucentis is approximately USD 2000, and with Eylea, it is around USD 1800. However, an average AMD treatment cost with Avastin is USD 50. Although Avastin carries a similarly high price tag, as Lucentis and Eylea, when used for colon cancer, in case of eye treatment, it is less expensive because only 1/40th of the drug is being used for each dose.

The global market for age-related macular degeneration is estimated to reach USD 11,186.8 million by 2023, from USD 7,128.4 million in 2017. The market is projected to grow at a CAGR of 7.80%, during the forecast period of 2017 to 2023.

On the basis of type, the market for age-related macular degeneration is segmented into dry age-related macular degeneration and wet age-related macular degeneration. By type, the market for wet age-related macular degeneration accounted for the largest market share in 2017.

On the basis of stages, the market for age-related macular degeneration is segmented into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. By stages, the market for intermediate age-related macular degeneration accounted for the largest market share in 2017.

The global age-related macular degeneration market, by age group, is segmented into above 40 years, above 60 years, and above 75 years. By age, the market for above 75 years accounted for the largest market share in 2017.

The global age-related macular degeneration, by diagnosis and treatment type, is segmented into diagnosis and treatment. The treatment segment holds the largest market share in the global age-related macular degeneration market, by diagnosis and treatment.

On the basis of route of administration, the global age-related macular degeneration market is segmented into intravenous, intravitreal, and others. The intravitreal segment dominates the global age-related macular degeneration market.

The global age-related macular degeneration market, on the basis of end-user, is segmented into hospitals and clinics, diagnostic centers, academic research institutes, and others. Hospitals and clinics hold the largest market share in the global age-related macular degeneration market.

Key Players

The key players for the age-related macular degeneration market are F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals co, and others.

Study Objectives

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries
  • To provide insights into factors influencing and affecting the market growth
  • To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
  • To provide economic factors that influence the global age-related macular degeneration market

Target Audience

  • Pharmaceutical and Medical Device Industries
  • Potential Investors
  • Medical Research Institutes
  • Key Executive (CEO and COO) and Strategy Growth Manager
  • Research Companies

Key Findings

  • The major market players in the global age-related macular degeneration market are F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals co, and others
  • F. Hoffmann-La Roche AG accounted for more than 13.2% share of the global age-related macular degeneration market
  • Based on type, the wet age-related macular degeneration segment commanded the largest market share in 2017 and was valued at USD 4,423.5 million in 2017
  • Based on stages, the intermediate Age-Related Macular Degeneration (AMD) segment commanded the largest market share in 2017 and was valued at USD 3,224.6 million in 2017
  • On the basis of region, the American region is projected to be the fastest growing region, at a CAGR of 7.86% during the forecast period

Regional Analysis

Americas

  • North America
    • US
    • Canada
  • South America

Europe

  • Western Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Rest of Western Europe
  • Eastern Europe

Asia-Pacific

    • China
    • Japan
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia-Pacific

The Middle East & Africa

  • Middle East
  • Africa

Table of Contents

1 Report Prologue

2 Executive Summary

3 Market Introduction

  • 3.1 Definition
  • 3.2 Scope of the Study
  • 3.3 Assumptions & Limitations
    • 3.3.1 Assumptions
    • 3.3.2 Limitations
  • 3.4 Market Structure

4 Research Methodology

  • 4.1 Research Process
  • 4.2 Primary Research
  • 4.3 Secondary Research
  • 4.4 Market Size Estimation
  • 4.5 Forecast Model

5 Market Dynamics

  • 5.1 Introduction
  • 5.2 Drivers
    • 5.2.1 Growing geriatric population and increasing prevalence of age-related macular degeneration
    • 5.2.2 Several branded drugs going off patent
  • 5.3 Restraints
    • 5.3.1 High cost associated with AMD
    • 5.3.2 Stringent FDA regulations
  • 5.4 Opportunities
    • 5.4.1 Strong pipeline
  • 5.5 Pipeline Analysis
    • 5.5.1 Brolucizumab 6 mg
    • 5.5.2 NCT01691261
    • 5.5.3 NCT03102138
    • 5.5.4 Lampalizumab
    • 5.5.5 RG7716
    • 5.5.6 Emixustat
    • 5.5.7 Zimura Dry AMD
    • 5.5.8 Zimura Wet AMD
    • 5.5.9 GSK933776
    • 5.5.10 RXI-109
    • 5.5.11 Abicipar Pegol

6 Market Factor Analysis

  • 6.1 Supply Chain Analysis
    • 6.1.1 R&D
    • 6.1.2 Parts Manufacturing
    • 6.1.3 Distribution
    • 6.1.4 Marketing & Sales
    • 6.1.5 Post-Sales Monitoring
  • 6.2 Porter's Five Forces Analysis
    • 6.2.1 Bargaining Power of Suppliers
    • 6.2.2 Bargaining Power of Buyers
    • 6.2.3 Threat of New Entrants
    • 6.2.4 Threat of Substitutes
    • 6.2.5 Intensity of Rivalry

7 Global Age-Related Macular Degeneration Market, by Type

  • 7.1 Overview
    • 7.1.1 Introduction
    • 7.1.2 Wet Age-Related Macular Degeneration (Wet AMD)
    • 7.1.3 Dry Age-Related Macular Degeneration (Dry AMD)

8 Global Age-Related Macular Degeneration Market, by Stages

  • 8.1 Overview
    • 8.1.1 Introduction
    • 8.1.2 Intermediate stage age-related macular degeneration
    • 8.1.3 Early-stage age-related macular degeneration
    • 8.1.4 Late stage age-related macular degeneration

9 Global Age-Related Macular Degeneration Market, by Age Group

  • 9.1 Overview
    • 9.1.1 Introduction
    • 9.1.2 Above 75 years
    • 9.1.3 Above 60 years
    • 9.1.4 Above 40 years

10 Global Age-Related Macular Degeneration Market, by Diagnosis & Treatment

  • 10.1 Overview
    • 10.1.1 Introduction
    • 10.1.2 Treatment
    • 10.1.3 Diagnosis

11 Global Age-Related Macular Degeneration Market, by Route of Administration

  • 11.1 Overview
    • 11.1.1 Introduction
    • 11.1.2 Intravitreal route of administration
    • 11.1.3 Intravenous route of administration

12 Global Age-Related Macular Degeneration Market, By End-User

  • 12.1 Overview
    • 12.1.1 Introduction
    • 12.1.2 Hospital & Clinics
    • 12.1.3 Diagnostic Centers
    • 12.1.4 Academic research institutes

13 Age-Related Macular Degeneration Market, by Region

  • 13.1 Introduction
  • 13.2 Americas
    • 13.2.1 North America
      • 13.2.1.1 U.S.
      • 13.2.1.2 Canada
    • 13.2.2 South America
  • 13.3 Europe
    • 13.3.1 Western Europe
      • 13.3.1.1 Germany
      • 13.3.1.2 France
      • 13.3.1.3 U.K
      • 13.3.1.4 Italy
      • 13.3.1.5 Spain
      • 13.3.1.6 Rest of Western Europe
    • 13.3.2 Eastern Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 Republic of Korea
    • 13.4.6 Rest of Asia Pacific
  • 13.5 The Middle East and Africa
    • 13.5.1 Middle East
    • 13.5.2 Africa

14 Competitive Landscape

  • 14.1 Company Market Share Analysis
    • 14.1.1 Introduction
  • 14.2 Key Strategic Analysis
    • 14.2.1 Introduction

15 Company Profiles

  • 15.1 Novartis AG
    • 15.1.1 Company Overview
    • 15.1.2 Financial Overview
    • 15.1.3 Products Offering
    • 15.1.4 Key Developments
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Strategy
  • 15.2 Pfizer Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Financial Overview
    • 15.2.3 Products Offering
    • 15.2.4 Key Developments
    • 15.2.5 SWOT Analysis
    • 15.2.6 Key Strategy
  • 15.3 F. Hoffmann-La Roche AG
    • 15.3.1 Company Overview
    • 15.3.2 Financial Overview
    • 15.3.3 Products Offering
    • 15.3.4 Key Developments
    • 15.3.5 SWOT Analysis
    • 15.3.6 Key Strategy
  • 15.4 Acucela Inc.
    • 15.4.1 Company Overview:
    • 15.4.2 Financial Overview
    • 15.4.3 Products Offering
    • 15.4.4 Key Developments
    • 15.4.5 SWOT Analysis
    • 15.4.6 Key Strategy
  • 15.5 Ophthotech Corporation
    • 15.5.1 Company Overview
    • 15.5.2 Financial Overview
    • 15.5.3 Products Offering
    • 15.5.4 Key Developments
    • 15.5.5 SWOT Analysis
    • 15.5.6 Key Strategy
  • 15.6 GlaxoSmithKline Plc.
    • 15.6.1 Company Overview
    • 15.6.2 Financial Overview
    • 15.6.3 Products Offering
    • 15.6.4 Key Developments
    • 15.6.5 SWOT Analysis
    • 15.6.6 Key Strategy
  • 15.7 Bayer AG
    • 15.7.1 Company Overview
    • 15.7.2 Financial Overview
    • 15.7.3 Products Offering
    • 15.7.4 Key Developments
    • 15.7.5 SWOT Analysis
    • 15.7.6 Key Strategy
  • 15.8 Rxi Pharmaceuticals, Inc.
    • 15.8.1 Company Overview
    • 15.8.2 Financial Overview
    • 15.8.3 Pipeline Products
    • 15.8.4 Key Developments
    • 15.8.5 SWOT Analysis
    • 15.8.6 Key Strategy
  • 15.9 Regeneron Pharmaceutical Inc.
    • 15.9.1 Company Overview
    • 15.9.2 Financial Overview
    • 15.9.3 Products Offering
    • 15.9.4 Key Developments
    • 15.9.5 SWOT Analysis
    • 15.9.6 Key Strategy
  • 15.1 Alimera Sciences Inc.
    • 15.10.1 Company Overview
    • 15.10.2 Financial Overview
    • 15.10.3 Pipeline Products
    • 15.10.4 Key Developments
    • 15.10.5 SWOT Analysis
    • 15.10.6 Key Strategy
  • 15.11 Santen Pharmaceuticals co.
    • 15.11.1 Company Overview
    • 15.11.2 Financial Overview
    • 15.11.3 Products Offering
    • 15.11.4 SWOT Analysis
    • 15.11.5 Key Developments
    • 15.11.6 Key Strategy
  • 15.12 ALLERGAN
    • 15.12.1 Company Overview
    • 15.12.2 Financial Overview
    • 15.12.3 Products Offering
    • 15.12.4 SWOT Analysis
    • 15.12.5 Key Developments
    • 15.12.6 Key Strategy
  • 15.13 Bausch & Lomb Incorporated
    • 15.13.1 Company Overview
    • 15.13.2 Financial Overview
    • 15.13.3 Products Offering
    • 15.13.4 Key Developments
    • 15.13.5 SWOT Analysis
    • 15.13.6 Key Strategy

16 Appendix

  • 16.1 Discussion Blue Print

List of Tables

  • TABLE 1 MARKET SYNOPSIS
  • TABLE 2 PRIMARY INTERVIEWS
  • TABLE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2017 & 2023
  • TABLE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY STAGES,, 2015-2023 (USD MILLION)
  • TABLE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTERMEDIATE AGE-RELATED MACULAR DEGENERATION(AMD),BY REGION, 2015-2023 (USD MILLION)
  • TABLE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR EARLY AGE-RELATED MACULAR DEGENERATION (AMD),BY REGION, 2015-2023 (USD MILLION)
  • TABLE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY LATE AGE-RELATED MACULAR DEGENERATION (AMD),BY REGION, 2015-2023 (USD MILLION)
  • TABLE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 60 YEARS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 13 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 40 YEARS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 14 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 15 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION)
  • TABLE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTRAVITREAL, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTRAVENOUS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY END USER, 2015-2023 (USD MILLION)
  • TABLE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ACADEMIC RESEARCH INSTITUTES CENTERS, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 31 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2017-2023 (USD MILLION)
  • TABLE 32 AMERICAS: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 33 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 34 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 35 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 36 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 37 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 38 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 39 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 40 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 41 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 42 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 43 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 44 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 45 AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 46 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 47 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 48 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 49 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 50 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 51 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 52 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 53 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 54 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 55 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 56 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 57 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 58 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 59 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 60 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 61 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 62 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 63 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 64 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 65 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 66 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 67 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 68 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 69 U.S. AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 70 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 71 U.S. AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 72 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 73 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 74 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 75 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 76 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 77 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 78 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 79 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 80 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 81 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 82 CANADA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 83 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 84 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 85 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 86 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 87 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 88 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 89 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 90 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 91 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 92 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 93 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 94 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 95 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 96 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 97 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 98 EUROPE: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2017-2023 (USD MILLION)
  • TABLE 99 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 100 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 101 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 102 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 103 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 104 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 105 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 106 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 107 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 108 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 109 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 110 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 111 EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 112 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 113 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 114 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 115 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 116 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 117 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 118 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 119 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 120 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 121 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 122 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 123 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 124 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 125 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 126 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 127 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 128 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 129 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 130 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 131 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 132 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 133 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 134 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 135 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 136 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 137 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 138 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 139 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 140 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 141 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 142 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 143 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 144 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 145 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 146 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 147 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 148 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 149 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 150 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 151 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 152 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 153 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 154 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 155 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 156 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 157 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 158 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 159 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 160 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 161 U.K AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 162 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 163 U.K AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 164 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 165 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 166 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 167 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 168 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 169 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 170 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 171 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 172 E-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 173 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 174 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 175 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 176 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 177 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 178 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 179 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 180 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 181 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 182 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 183 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 184 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 185 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 186 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 187 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 188 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 189 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 190 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 191 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 192 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 193 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 194 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 195 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 196 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 197 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 198 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 199 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 200 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 201 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 202 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 } (USD MILLION)
  • TABLE 203 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 204 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 205 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 206 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 207 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 208 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 209 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 210 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 211 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 212 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 213 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 214 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 215 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2017-2023 (USD MILLION)
  • TABLE 217 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 218 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 219 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 220 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 221 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 222 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 223 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 224 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 225 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 226 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 227 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 228 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 229 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 230 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 231 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 232 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 233 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 234 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 235 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 236 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 237 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 238 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 239 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 240 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 241 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 242 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 243 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 244 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 245 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 246 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 247 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 248 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 249 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 250 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 251 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 252 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 253 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 254 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 255 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 256 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 257 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 258 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 259 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 260 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 261 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 262 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 263 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 264 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 265 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 266 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 267 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 268 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 269 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 270 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 271 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 272 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 273 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 274 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 275 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 276 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 277 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 278 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 279 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 280 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 281 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 282 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 283 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 284 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 285 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 286 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 287 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 288 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 289 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 290 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 291 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 292 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 293 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 294 REPUBLIC OF KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 295 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 296 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 297 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 298 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 299 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 300 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 301 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 302 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 303 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 304 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 305 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 306 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 307 REST OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 308 THE MIDDLE EAST AND AFRICA: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2017-2023 (USD MILLION)
  • TABLE 309 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 310 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 311 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 312 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 313 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 314 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 315 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 316 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 317 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 318 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 319 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 320 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 321 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 322 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 323 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 324 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 325 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 326 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 327 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 328 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 329 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 330 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 331 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 332 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 333 MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)
  • TABLE 334 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 335 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2015-2023 (USD MILLION)
  • TABLE 336 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2015-2023 (USD MILLION)
  • TABLE 337 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2015-2023 (USD MILLION)
  • TABLE 338 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 339 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2015-2023 (USD MILLION)
  • TABLE 340 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI- VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2015-2023 (USD MILLION)
  • TABLE 341 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 342 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 343 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 344 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 345 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2015-2023 (USD MILLION)
  • TABLE 346 AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2015-2023 (USD MILLION)

List of Figures

  • FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET
  • FIGURE 5 SUPPLY CHAIN: AGE-RELATED MACULAR DEGENERATION MARKET
  • FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2017 (% SHARE)
  • FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2017 (% SHARE)
  • FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2017 & 2023
  • FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2017 (% SHARE)
  • FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2017 & 2023
  • FIGURE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2017 (% SHARE)
  • FIGURE 13 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2017 & 2023
  • FIGURE 14 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2017 (% SHARE)
  • FIGURE 15 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2017 & 2023
  • FIGURE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2017 (% SHARE)
  • FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2017 & 2023
  • FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2017 & 2023 (USD MILLION)
  • FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2017 (% SHARE)
  • FIGURE 20 AMERICAS: AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 21 EUROPE: AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 22 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 23 THE MIDDLE EAST AND AFRICA: AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, MARKET SHARE ANALYSIS 2017 (%)
  • FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET: KEY STRATEGIC ANALYSIS 2017 (%)
Back to Top